life sciences

Life Sciences Transfer Pricing

CRA leverages cross-functional expertise to deliver best-in-class services to clients in the Life Sciences sector including strategic consulting, IP litigation, antitrust, and transfer pricing.  Life sciences companies have high-stakes transfer pricing issues due to their high-value IP and the risks embedded within the value chain.  CRA’s transfer pricing economists have assisted numerous pre-clinical biotech companies with their initial international expansion and IP planning; and commercial-phase companies design and document intercompany pricing policies relating to their physical goods supply chains.  CRA experts have provided expert witness reports in GlaxoSmithKline vs. Commissioner and in state transfer pricing disputes.

Meet our team


  • 01
    Global transfer pricing advisory
    CRA was engaged by a leading global medical device company to provide global transfer pricing advisory.  CRA has been instrumental in all parts of its transfer...
    View engagement
  • 02
    Dispute Resolution
    A biotechnology firm is in dispute with a tax authority regarding intercompany pricing of licenses and related transactions with its foreign subsidiary. A CRA...
    View engagement
  • 03
    Life Sciences Transfer Pricing
    CRA was engaged by a market leading medical device company to assist with a business restructuring to consolidate its IP ownership within the group structure...
    View engagement

Subscribe to receive our latest Insights.